199 results on '"Logunov, Denis Y"'
Search Results
2. Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain
3. Structural insight into recognition of Clostridioides difficile toxin A by novel neutralizing nanobodies targeting QTIN-like motifs within its receptor-binding domain
4. New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses
5. Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy
6. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
7. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
8. Immunogenicity and Efficacy of Combined mRNA Vaccine Against Influenza and SARS-CoV-2 in Mice Animal Models.
9. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
10. Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response
11. Major Role of S-Glycoprotein in Providing Immunogenicity and Protective Immunity in mRNA Lipid Nanoparticle Vaccines Based on SARS-CoV-2 Structural Proteins
12. Human TRIM14 protects transgenic mice from influenza A viral infection without activation of other innate immunity pathways
13. Synthesis and Antiviral Activity of Novel β-D-N4-Hydroxycytidine Ester Prodrugs as Potential Compounds for the Treatment of SARS-CoV-2 and Other Human Coronaviruses
14. Antigenic Architecture of the H7N2 Influenza Virus Hemagglutinin Belonging to the North American Lineage
15. Receptor Mincle promotes skin allergies and is capable of recognizing cholesterol sulfate
16. Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
17. In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
18. Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study
19. Antigenic Architecture of the H7N2 Influenza Virus Hemagglutinin Belonging to the North American Lineage.
20. Synthesis and Antiviral Activity of Novel β-D-N4-Hydroxycytidine Ester Prodrugs as Potential Compounds for the Treatment of SARS-CoV-2 and Other Human Coronaviruses.
21. rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
22. Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A
23. Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level
24. Dynamics of SARS-CoV-2 Major Genetic Lineages in Moscow in the Context of Vaccine Prophylaxis
25. Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus
26. Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection
27. Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A
28. Sputnik Light and Sputnik V Vaccination Is Effective at Protecting Medical Personnel from COVID-19 during the Period of Delta Variant Dominance
29. rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis
30. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
31. Antiviral Activity of N1,N3-Disubstituted Uracil Derivatives against SARS-CoV-2 Variants of Concern
32. Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection
33. Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2)
34. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist
35. Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance
36. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals
37. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study
38. COVID-19 vaccination and HIV-1 acquisition
39. Boosting of the SARS-CoV-2–Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine
40. Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
41. Production of recombinant human lactoferrin in the allantoic fluid of embryonated chicken eggs and its characteristics
42. Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level.
43. Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern, including Omicron variant
44. A Deep Look Into COVID-19 Severity Through Dynamic Changes in Blood Cytokine Levels
45. Boosting of the SARS-CoV-2-specific immune response after vaccination with single-dose Sputnik Light vaccine
46. One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow
47. Development of adenoviral vector-based mucosal vaccine against influenza
48. SARS-CoV-2 specific T cells and antibodies in COVID-19 protection: a prospective study
49. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants
50. Antiviral Activity of N 1 ,N 3 -Disubstituted Uracil Derivatives against SARS-CoV-2 Variants of Concern.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.